Batavia and Candel partner up to develop and manufacture immunotherapies for brain tumors

Woburn and Needham, MA. &ndash; Contract Development and Manufacturing Organization (CDMO) Batavia Biosciences  has entered into a partnership with Candel Therapeutics,  a clinical stage biopharmaceutical company, to accelerate the development and production of CAN-3110, an oncolytic viral immunotherapy for glioma brain tumors, based on a replication attenuated Herpes Simplex Virus (HSV).&nbsp;
Batavia Biosciences will use its&nbsp;HIP-Vax&nbsp;technology&nbsp;to develop a highly intensified, scalable and robust manufacturing process for Candel Therapeutics. This work will enable the production of CAN-3110 for toxicity studies and establish a Good Manufacturing Practice (GMP) process for pending clinical trials.